| Cardior Pharmaceuticals–BMS: investment, 201705 financing round Series A totalling €15m incl co-lead investor BMS |
2017-05-11 |
| Cardior Pharmaceuticals–Boehringer: investment, 201705 financing round Series A totalling €15m incl co-lead investor BIVF |
2017-05-11 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 201705 financing round Series A totalling €15m incl co-lead investor HTGF |
2017-05-11 |
| Cardior Pharmaceuticals–Life Sciences Partners: investment, 201705 financing round Series A totalling €15m incl co-lead investor LSP |
2017-05-11 |
| Cardior Pharmaceuticals–SEVERAL: investment, 201705 financing round Series A €15m led by LSP + BIVF + BMS + BioMedPartners + HTGF |
2017-05-11 |
| Numaferm–EU (govt): investment, 201705 seed financing round totalling €7-digit incl European Investment Fund |
2017-05-11 |
| Numaferm–High-Tech Gründerfonds: investment, 201705 seed financing round totalling €7-digit incl HTGF |
2017-05-11 |
| Numaferm–PERSON: investment, 201705 seed financing round totalling €7-digit incl business angels + Qiagen founders Detlev Riesner + Jürgen Schumacher |
2017-05-11 |
| Numaferm–SEVERAL: investment, 201705 seed financing round €7-digit from HTGF + Detlev Riesner + Jürgen Schumacher + EIF |
2017-05-11 |
| BC Platforms–Debiopharm: investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| BC Platforms–SEVERAL: investment, 201705 financing round Series B $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| BC Platforms–Tesi (FI): investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| Grzybowski Scientific Inventions–Merck (DE): investment, 201705 acquisition of GSI by Merck |
2017-05-09 |
| Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund |
2017-05-08 |
| Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al |
2017-05-08 |
| CRISPR Therapeutics–MIT: lipid nanoparticle technolgy, 201705– excl license for family of LNP technologies for in vivo gene editing applications |
2017-05-08 |
| Genetrix (ES)–SEVERAL: investment, 201705– capital increase up to €10m w rights offering + private placement Sygnis AG |
2017-05-08 |
| Innova Biosciences–Genetrix (ES): investment, 201705–201707 acquisition €8m cash + 2m Sygnis shares plus up to 1.5m shares by Sygnis AG |
2017-05-08 |
| Luxendo–Bruker: investment, 201705 acquisition €na of Luxendo GmbH by Bruker |
2017-05-08 |
| Medigene–SEVERAL: investment, 201705 private placement €20.7m 1.965m new shares at €10.55/share to institutional investors |
2017-05-04 |
| MVZ für Laboratoriumsmedizin am Hygiene-Institut–Eurofins: investment, 201705– acquisition of Hygel by Eurofins ANNOUNCED |
2017-05-04 |
| Vivet Therapeutics–Columbus Venture Partners: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor CVP |
2017-05-04 |
| Vivet Therapeutics–Kurma: investment, 201705 financing round Series A totalling €37.5m incl co-investor Kurma Partners |
2017-05-04 |
| Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund |
2017-05-04 |
| Vivet Therapeutics–Odlander Fredrikson: investment, 201705 financing round Series A totalling €37.5m incl co-investor HealthCap |
2017-05-04 |
| Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund |
2017-05-04 |
| Vivet Therapeutics–SEVERAL: investment, 201705 financing round Series A €37.5m led by Novartis Venture Fund + Columbus Venture Partners |
2017-05-04 |
| Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital |
2017-05-04 |
| AstraZeneca–Pieris: anticalin technology, 201705– collab developm + commerc $57.5m upfront + near-term inhaled respiratory drugs incl PRS-060 |
2017-05-03 |
| PharmaCell–Lonza: investment, 201704 acquisition of PharmaCell BV by Lonza |
2017-05-03 |
| ImCheck Therapeutics–Boehringer: investment, 201705 financing round Series A totalling €20m incl co-lead investor BIVF |
2017-05-02 |
| ImCheck Therapeutics–Gimv: investment, 201705 financing round Series A totalling €20m incl co-investor Gimv |
2017-05-02 |
| ImCheck Therapeutics–Idinvest Partners: investment, 201705 financing round Series A totalling €20m incl co-lead investor Idinvest |
2017-05-02 |
| ImCheck Therapeutics–Kurma: investment, 201705 financing round Series A totalling €20m incl co-lead investor Kurma Partners |
2017-05-02 |
| ImCheck Therapeutics–Life Sciences Partners: investment, 201705 financing round Series A totalling €20m incl co-investor LSP |
2017-05-02 |
| ImCheck Therapeutics–SEVERAL: investment, 201705 financing round Series A €20m from BIVF + Kurma Partners + Idinvest + Gimv + LSP |
2017-05-02 |
| Magenta Therapeutics–Novartis: cell therapy product, 201705– license to MGTA-456 (HSC835) to expand cord blood stem cells for transplants |
2017-05-02 |
| Magenta Therapeutics–SEVERAL: investment, 201705 financing round Series B $50m led by GV + incl Atlas Venture + Third Rock Ventures et al |
2017-05-02 |
| Noxxon–SEVERAL: investment, 201705 private placement €1m capital increase incl €250k fron YA II PN Ltd |
2017-05-02 |
| Noxxon–Yorkville: credit, 201705–201811 convertible bonds up to €10m to YA II PN Ltd TERMINATED 11/18 |
2017-05-02 |
| Caladrius–Hitachi: investment, 201705 acquisition of PCT LLC by Hitachi Chemical |
2017-05-01 |
| Aduro Biotech–Univ Bonn: cancer immunotherapy, 201704– license for STING agonists via Provendis to Aduro Biotech |
2017-04-27 |
| Arsanis–SEVERAL: investment, 201704 financing round Series D $45.5m led by Gates Foundation + incl GV + Alexandria Venture Investments et al |
2017-04-26 |
| Epigenomics–SEVERAL: investment, 201704–201707 public cash takeover offer €7.52/share FAILED valuing ECX at €171m incl net cash by CFUC + Biochain |
2017-04-26 |
| Microsaic–SCPA GmbH: chromatography software, 201704– collab integration of 4000 MiD MS system with PrepCon 5 preparative data + control s/w |
2017-04-26 |
| EMBL–Enamine: chemical compound library, 201704– collab library synthesis + medical chemistry + biological services for cancer drug research |
2017-04-25 |
| Forge Therapeutics–Evotec: investment, 201704 financing round Series A totalling $15m incl co-investor Evotec AG |
2017-04-25 |
| Forge Therapeutics–SEVERAL: investment, 201704 financing round Series A $15m led by MagnaSci Ventures + incl Evotec + Alexandria Venture et al |
2017-04-25 |
| KSK Diagnostics–Hamburg (govt): investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg |
2017-04-24 |
| KSK Diagnostics–High-Tech Gründerfonds: investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg |
2017-04-24 |
| KSK Diagnostics–SEVERAL: investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg |
2017-04-24 |
| Merck (DE)–Fresenius: investment, 201704–201709 acquisition €156m upfront + €500m milestones + royalties of Merck biosimilars business in Vaud CH |
2017-04-24 |
| Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp |
2017-04-24 |
| BioInvent–Merck (DE): bioreactors, 201704 supply full line of Mobius single-use bioreators to BioInvent upstream facility in Lund |
2017-04-20 |
| Seracell Pharma–Vita 34: investment, 201704– conditional 100% acquisition of up to €14m ANNOUNCED |
2017-04-20 |
| Gustavus Adolphus College–Agilent: grant, 201704– Thought Leader Award to Dwight Stoll to for 2D-LC research |
2017-04-19 |
| Hookipa–Instinctif Partners: public relations, 201704 service existent by Instinctif Partners |
2017-04-19 |
| Thermo Fisher–Univ Basel: DNA sequencing, 201704– collab Univ Hospital joins NGS Companion Dx Center of Excellence Program |
2017-04-18 |
| Bayer–Ten Bridge Communications: public relations, 201704 service existent CRISR Tx/Bayer jv Casebia by Ten Bridge |
2017-04-17 |
| CRISPR Therapeutics–StrideBio: AAV vectors, 201704– collab developm + license option usingStrideBio’s vectors for in vivo CRISPR/Cas9-based therapies |
2017-04-17 |
| MOCON–AMETEK: investment, 201704– acquisition of MOCON Inc for aggregate enterprise value of $182m |
2017-04-17 |
| Polyphor–SEVERAL: investment, 201704 private financing round CHF40m with CHF10m upfront + CHF30m at positive ph2 study end in 2017H2 |
2017-04-12 |
| Adhesys Medical–Grünenthal: investment, 201704 acquisition of Adhesys by Grünenthal |
2017-04-07 |
| Adhesys Medical–GSK Stockmann: legal services, 201704 supply legal advisor for sale of Adhesys Medical to Grünenthal |
2017-04-07 |
| Biotest–Ashurst: legal services, 201704 supply service legal advisor with regard to sale of Biotest AG to Ceat Group (CN) |
2017-04-07 |
| Asceneuron–Instinctif Partners: public relations, 201704 service existent by Instinctif Partners |
2017-04-06 |
| Berlin Institute of Health–Labfolder: electronic lab notebook, 201704– supply license Labfolder s/w to BIH (Charité + MDC) |
2017-04-06 |
| Labfolder–MC Services: public relations, 201704 service existent by MC Services AG |
2017-04-06 |
| Novartis–Lubris: rh lubricin, 201704– license €na exercise of option for ECF843 for ophthalmic indications ww excl Europe |
2017-04-06 |
| Biosyntia–FGen: biological vitamin production, 201704– collob developm of microbial strains for production of specific B vitamins |
2017-04-05 |
| MTIP MedTech Innovation Partners–SEVERAL: investment, 201704 final closing w addit CHF30m bringing total fund size of 1st MTIP Fund to CHF60m |
2017-04-04 |
| Topas Therapeutics–MC Services: public relations, 201704 service existent by MC Services AG |
2017-04-04 |
| MKS Instruments–Sartorius: investment, 201704 acquisition $72.5m of MKS Instruments AB (Umetrics) by Sartorius Stedim Biotech |
2017-04-03 |
| Bentekk–Dräger: investment, 201704 acquisition of majority stake by Dräger |
2017-04-01 |
| Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH |
2017-04-01 |
| Eisai–Calypso Biotech: therapeutic antibody, 201703– ww license + collab for MMP-9 MAb CALY-001 with EA Pharma Co Ltd |
2017-03-31 |
| Innovative Medicines Initiative–Qiagen: cancer biomarker, 201703– collab Qiagen joins CANCER-ID project |
2017-03-30 |
| Novartis–Oxford BioMedica: lentiviral vector technology, 201703 supply existent OBM sole producer of lentiviral vector expressing CTL019 |
2017-03-30 |
| Symetis–Boston Scientific: investment, 201703– acquisition $435m in cash ANNOUNCED |
2017-03-30 |
| Biotest–Creat (CN): investment, 201703–201801 public cash tender offer €1.3b incl net debt for all shares w €28.5/ordinary + €19m/preference share |
2017-03-29 |
| Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners |
2017-03-29 |
| Bayer–Icagen: drug discovery assays, 201703– collab developm of XRpro Assays for early discovery programs in area of transporter targets |
2017-03-28 |
| Menarini–Selvita: kinase inhibitor, 201703– license ww to dual PIM/FLT3 kinase inhibitor SEL24 to Berlin-Chemie |
2017-03-28 |
| Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody |
2017-03-28 |
| Institut Pasteur–Bruker: NMR spectrometer, 201703 supply existent early customer for AVANCE NEO 800 MHz system |
2017-03-27 |
| PureTech Health–Novartis: investment, 201703 equity position in new resTORbio subsidary for Novartis as part of mTORC1 inhibitor license deal |
2017-03-24 |
| PureTech Health–Novartis: mTORC1 inhibitors, 201703– license excl to 2 clin stage programs to be developed by new resTORbio subsidary |
2017-03-24 |
| Numares–Univ Oxford: NMR-based IVD tests, 201703– collab developm of multiple sclerosis test using Axinon IVD system + MGS technology |
2017-03-23 |
| BASF–MIT: CRISPR technology, 201703– license ww for agricultural + industrial microbiology applications from Broad Institute |
2017-03-22 |
| Symetis–SEVERAL: investment, 201703 IPO at Euronext NOT REALISED because of acquistion offer by Boston Scientific |
2017-03-17 |
| Medac–Cevec: rec protein production technology, 201703– license to CAP GT technology for oncology products |
2017-03-16 |
| Provecs–Cevec: rec protein production technology, 201703– license non-excl extension to CAP GT technology for cancer immunotherapy |
2017-03-16 |
| CRISPR Therapeutics–MaxCyte: gene transfer technology, 201703– license non-excl to CRISPR Tx + Caseio for using Flow Electroporation technology |
2017-03-14 |
| NeoGenomics–AstraZeneca: cancer research tests, 201703– collab using automated Definiens biomarker solutions for IHC services of NeoGenomics |
2017-03-13 |
| ILC Micro-Chem–SGS: investment, 201703 acquisition of ILC by SGS |
2017-03-09 |
| Breath Therapeutics–Gimv: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–MC Services: public relations, 201703 service existent by MC Services AG |
2017-03-08 |
| Breath Therapeutics–SEVERAL: investment, 201703 financing round Series A €43.5m co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–Sofinnova: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Fresenius–Wacker: rec protein production, 201703 collab use of Wacker Biotech’s FOLDTEC technology to produce Fabs for Fresenius |
2017-03-08 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 31 32 33 ... 36 37 38 
Date![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px](/banner/iito-business-intelligence-20220406-650-300-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
